EPISODE · Jun 3, 2026 · 1 MIN
FDA Approves IND for Phase 3 Trial of iSCIB1+ in Melanoma
from TheBrief.Health · host TheBrief.Health
FDA approval of a phase 3 trial for the iSCIB1+ melanoma vaccine advances personalized cancer treatment, offering potential survival benefits for patients with advanced disease.
What this episode covers
FDA approval of a phase 3 trial for the iSCIB1+ melanoma vaccine advances personalized cancer treatment, offering potential survival benefits for patients with advanced disease.
NOW PLAYING
FDA Approves IND for Phase 3 Trial of iSCIB1+ in Melanoma
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m